Developer docs
API playgroundTry for free, no card

Search company profiles

CytomX Therapeutics

Full company profile

uuid0000oj9

Namestring
CytomX Therapeutics
Legal namestring
CytomX Therapeutics, Inc.
Websiteurl
cytomx.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

CytomX Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, founded in 2010 and publicly traded on NASDAQ under the ticker CTMX. The company develops conditionally activated antibody therapeutics built on its proprietary Probody platform, in which a masking domain keeps an antibody inactive in healthy tissue and is cleaved by proteases enriched in the tumor microenvironment, enabling selective activation at the tumor site. The platform has been applied across multiple modalities, including antibody-drug conjugates (Varseta-M/CX-2051, an EpCAM-targeted ADC with a Topo-1 payload), T-cell engaging bispecifics (CX-908 targeting P-Cadherin x CD3), and cytokine therapeutics (CX-801, an interferon alpha-2b Probody). Lead clinical programs target metastatic colorectal cancer and advanced melanoma, with a registrational trial for Varseta-M planned for the first half of 2027.

CytomX operates a hybrid business model that combines a wholly-owned pipeline with a portfolio of strategic collaborations. Revenue is generated through licensing arrangements with major pharmaceutical partners — Regeneron, Bristol Myers Squibb, Amgen, and Moderna — comprising upfront payments, research funding, development and regulatory milestones, and tiered royalties on future net product sales, with over $400 million in committed payments from these partners as of early 2026. The company raised an additional $250 million via public offering in March 2026 to support pipeline development, bringing its cash position to approximately $346.7 million with runway projected into at least the second half of 2028. CytomX's marketed positioning emphasizes the Probody platform's ability to address historically "undruggable" tumor antigens by widening the therapeutic window, validated clinically by Phase 1 expansion data for Varseta-M showing a 32% confirmed response rate and 88% disease control rate in late-line metastatic colorectal cancer without EpCAM-class toxicities.

The company markets through scientific publications, presentations at major oncology congresses, and investor conferences, with clinical trials as the primary channel for advancing drug candidates. There are no commercially approved products, and all drug candidates are investigational; CytomX has between 101 and 250 employees, operates from a single South San Francisco headquarters, and is incorporated in Delaware, USA.

Short descriptiontext

CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics on its Probody platform for solid tumors, with lead programs in metastatic colorectal cancer and melanoma. The company generates revenue through licensing and milestone payments from partnerships with Regeneron, Bristol Myers Squibb, Amgen, and Moderna.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, oncology drug development, biopharmaceutical research, targeted cancer therapy, conditional antibody activation
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership/Collaboration Revenue
TypeLicensing Royalties
Description

CytomX generates revenue through strategic partnerships with pharmaceutical companies including Regeneron, Bristol Myers Squibb, Amgen, and Moderna. Revenue includes upfront payments, research funding, preclinical/clinical milestone payments, regulatory milestones, and tiered royalties on net product sales. The company had over $400 million in committed payments from partners as of early 2026.

cytomx.com
2Public Stock Offering
TypeOne Time License
Description

CytomX raised $250 million in March 2026 through a public offering of common stock and pre-funded warrants to fund pipeline development, capital expenditures, and general corporate purposes.

ir.cytomx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PROBODY
Description

Proprietary therapeutic platform technology that engineers antibody therapeutics to remain masked until they encounter active proteases in the tumor microenvironment.

cytomx.com
Core offering1 text field

CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics (Probodies) for cancer treatment. Its pipeline includes lead candidate Varseta-M (CX-2051), an EpCAM-targeting antibody-drug conjugate for metastatic colorectal cancer, plus CX-801 (masked interferon alpha-2b cytokine) and CX-908 (a P-Cadherin x CD3 Probody T-cell engager). The company's core innovation is the Probody platform, which masks antibody activity until cleavage by tumor-associated proteases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 32% confirmed response rate at 10 mg/kg dose in late-line metastatic colorectal cancer patients
+3 more records
Product overview1 text field

CytomX Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of conditionally activated cancer therapeutics built on its proprietary PROBODY platform. The platform enables antibody-based therapies to remain masked in healthy tissue and activate specifically within tumor microenvironments. The core product portfolio includes Varseta-M (CX-2051), an EpCAM-directed ADC for metastatic colorectal cancer; CX-801, an interferon alpha-2b Probody cytokine for advanced melanoma; and CX-908, a P-Cadherin x CD3 T-cell engaging bispecific for solid tumors. These programs represent the company's wholly-owned pipeline, supplemented by strategic collaborations with partners including Regeneron, Amgen, Bristol Myers Squibb, and Moderna.

Product and service4 records
1Varseta-M (CX-2051)
CategoryOncology Biologics / Antibody-Drug Conjugate
Description

An EpCAM-targeting antibody-drug conjugate built on the Probody platform, in clinical development for metastatic colorectal cancer and other EpCAM-expressing solid tumors. Designed to deliver a cytotoxic payload preferentially to tumor tissue via conditional antibody activation.

2CX-801
CategoryOncology Biologics / Cytokine Therapy
Description

A masked (conditionally activated) interferon alpha-2b Probody cytokine designed to concentrate interferon activity within the tumor microenvironment while limiting systemic exposure and associated toxicity.

3CX-908
CategoryOncology Biologics / T-cell Engager
Description

A Probody-format T-cell engager bispecific targeting P-Cadherin on tumor cells and CD3 on T cells, designed to engage T-cell cytotoxicity preferentially in tumor tissue and reduce systemic T-cell activation.

4Probody Therapeutic Platform
CategoryTherapeutic Platform Technology
Description

CytomX's proprietary antibody engineering platform that generates conditionally activated biologics by incorporating a masking peptide linked via a protease-cleavable substrate, restricting activity to protease-rich environments such as tumors. The platform underpins both CytomX's internal pipeline and partner programs with Regeneron, Bristol-Myers Squibb, Amgen, and Moderna.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Strategic collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies for cancer and other diseases. CytomX received $35 million upfront including $5 million pre-paid research funding. Potential milestones up to approximately $1.2 billion plus tiered royalties on global net sales. Moderna leads clinical development and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-03
Description

Strategic collaboration to create conditionally-activated investigational bispecific cancer therapies combining CytomX's Probody platform with Regeneron's Veloci-Bi bispecific antibody platform. Initial agreement (2022) valued at up to $2 billion plus royalties. Expanded June 2026 with $37 million target selection payment for two additional programs, bringing total potential value to $4 billion with option for six more targets. CytomX receives upfront, milestone, and tiered global net sales royalty payments.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-03-01
Description

Collaboration to co-develop Probody T-cell-engaging bispecific therapeutics targeting CD3 receptor and select oncology targets. Originally valued at up to $1.68 billion with $80 million upfront. Astellas terminated the partnership in Q2 2025 after choosing not to advance remaining preclinical programs, despite positive Phase 1 data for CytomX's Probody platform.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Strategic immuno-oncology collaboration focused on research and development of T-cell-engaging bispecific therapeutics. Lead program CX-904 was discontinued in 2025 by mutual decision. Amgen has exclusive worldwide rights to develop up to three additional undisclosed targets, with CytomX eligible for upfront, milestone payments and high single-digit to mid-double digit royalties. CytomX also received rights to a preclinical T-cell engaging bispecific program.

5Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple targets using CytomX's Probody platform. Expanded in 2017 with $200 million upfront payment. Five oncology targets selected, with two remaining in preclinical development. CytomX eligible for future development, regulatory and sales milestone payments plus tiered royalties on net sales.

cytomx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC developer building a pipeline of conditionally activated and immune-stimulatory ADCs in oncology. Highly comparable to CytomX's Probody ADC approach in technology class, clinical-stage profile, and partnership-driven business model.

TypeDirect peer
Description

Pioneer in antibody-drug conjugates for oncology, now part of AbbVie. Direct precedent for clinical-stage ADC platform companies achieving strategic exits, validating CytomX's ADC-centric pipeline strategy.

TypeEmerging player
Description

Privately held, clinical-stage ADC developer focused on next-generation oncology therapeutics. Comparable emerging ADC player leveraging proprietary linker-payload technology with similar therapeutic ambitions.

TypeDirect peer
Description

Clinical-stage biotech engineering monoclonal antibodies and bispecifics with XmAb platform technology. Comparable in platform-based engineering of antibody therapeutics and partnership-driven monetization.

TypeDirect peer
Description

Clinical-stage oncology biotech developing bispecific antibodies and ADCs. Comparable clinical-stage pipeline, oncology focus, and reliance on strategic pharma partnerships.

TypeDirect peer
Description

Developed T-cell engaging bispecifics (TriTAC platform) for solid tumors, recently acquired by Merck. Comparable T-cell engager strategy and clinical-stage oncology focus, providing a recent exit benchmark for CytomX's bispecific work.

TypeEmerging player
Description

Clinical-stage bispecific antibody developer in oncology. Comparable small-cap clinical biotech with platform technology and partnership opportunities in bispecific antibody space.

TypeBroad incumbent
Description

Major biopharma developing Veloci-Bi bispecifics and antibody therapeutics; also a CytomX collaboration partner. Comparable as a broad incumbent in bispecific antibody development that validates CytomX's target space.

TypeBroad incumbent
Description

Pioneer of BiTE T-cell engager platform and active ADC developer; also a CytomX partner. Comparable as a large incumbent whose platform choices (and recent CX-904 discontinuation) directly influence CytomX's competitive context.

10Bristol Myers Squibb
TypeBroad incumbent
Description

Global biopharma with established immunotherapy, ADC, and bispecific franchises; longstanding CytomX collaboration partner since 2014. Relevant as both strategic partner and broader benchmark for the oncology platform partnering model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CytomX Therapeutics

Oncology Biopharmaceuticalscytomx.com

CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics on its Probody platform for solid tumors, with lead programs in metastatic colorectal cancer and melanoma. The company generates revenue through licensing and milestone payments from partnerships with Regeneron, Bristol Myers Squibb, Amgen, and Moderna.

What CytomX Therapeutics does

CytomX Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, founded in 2010 and publicly traded on NASDAQ under the ticker CTMX. The company develops conditionally activated antibody therapeutics built on its proprietary Probody platform, in which a masking domain keeps an antibody inactive in healthy tissue and is cleaved by proteases enriched in the tumor microenvironment, enabling selective activation at the tumor site. The platform has been applied across multiple modalities, including antibody-drug conjugates (Varseta-M/CX-2051, an EpCAM-targeted ADC with a Topo-1 payload), T-cell engaging bispecifics (CX-908 targeting P-Cadherin x CD3), and cytokine therapeutics (CX-801, an interferon alpha-2b Probody). Lead clinical programs target metastatic colorectal cancer and advanced melanoma, with a registrational trial for Varseta-M planned for the first half of 2027.

CytomX operates a hybrid business model that combines a wholly-owned pipeline with a portfolio of strategic collaborations. Revenue is generated through licensing arrangements with major pharmaceutical partners — Regeneron, Bristol Myers Squibb, Amgen, and Moderna — comprising upfront payments, research funding, development and regulatory milestones, and tiered royalties on future net product sales, with over $400 million in committed payments from these partners as of early 2026. The company raised an additional $250 million via public offering in March 2026 to support pipeline development, bringing its cash position to approximately $346.7 million with runway projected into at least the second half of 2028. CytomX's marketed positioning emphasizes the Probody platform's ability to address historically "undruggable" tumor antigens by widening the therapeutic window, validated clinically by Phase 1 expansion data for Varseta-M showing a 32% confirmed response rate and 88% disease control rate in late-line metastatic colorectal cancer without EpCAM-class toxicities.

The company markets through scientific publications, presentations at major oncology congresses, and investor conferences, with clinical trials as the primary channel for advancing drug candidates. There are no commercially approved products, and all drug candidates are investigational; CytomX has between 101 and 250 employees, operates from a single South San Francisco headquarters, and is incorporated in Delaware, USA.

CytomX Therapeutics firmographics

Firmographics
Name
CytomX Therapeutics
Legal name
CytomX Therapeutics, Inc.
Website
https://cytomx.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
101–250 employees
Short description
CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics on its Probody platform for solid tumors, with lead programs in metastatic colorectal cancer and melanoma. The company generates revenue through licensing and milestone payments from partnerships with Regeneron, Bristol Myers Squibb, Amgen, and Moderna.
Ownership category
akta.pro rank

CytomX Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody therapeutics
  • Oncology drug development
  • Biopharmaceutical research
  • Targeted cancer therapy
  • Conditional antibody activation

Where CytomX Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CytomX Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Partnership/Collaboration Revenue: CytomX generates revenue through strategic partnerships with pharmaceutical companies including Regeneron, Bristol Myers Squibb, Amgen, and Moderna. Revenue includes upfront payments, research funding, preclinical/clinical milestone payments, regulatory milestones, and tiered royalties on net product sales. The company had over $400 million in committed payments from partners as of early 2026.
  2. Public Stock Offering: CytomX raised $250 million in March 2026 through a public offering of common stock and pre-funded warrants to fund pipeline development, capital expenditures, and general corporate purposes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

CytomX Therapeutics product offering

Product offering

Core offering

CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics (Probodies) for cancer treatment. Its pipeline includes lead candidate Varseta-M (CX-2051), an EpCAM-targeting antibody-drug conjugate for metastatic colorectal cancer, plus CX-801 (masked interferon alpha-2b cytokine) and CX-908 (a P-Cadherin x CD3 Probody T-cell engager). The company's core innovation is the Probody platform, which masks antibody activity until cleavage by tumor-associated proteases.

Product overview

CytomX Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of conditionally activated cancer therapeutics built on its proprietary PROBODY platform. The platform enables antibody-based therapies to remain masked in healthy tissue and activate specifically within tumor microenvironments. The core product portfolio includes Varseta-M (CX-2051), an EpCAM-directed ADC for metastatic colorectal cancer; CX-801, an interferon alpha-2b Probody cytokine for advanced melanoma; and CX-908, a P-Cadherin x CD3 T-cell engaging bispecific for solid tumors. These programs represent the company's wholly-owned pipeline, supplemented by strategic collaborations with partners including Regeneron, Amgen, Bristol Myers Squibb, and Moderna.

Differentiator

Problem solved

Functional benefit

Brands

  • PROBODY: Proprietary therapeutic platform technology that engineers antibody therapeutics to remain masked until they encounter active proteases in the tumor microenvironment.

Products and services

  • Varseta-M (CX-2051) An EpCAM-targeting antibody-drug conjugate built on the Probody platform, in clinical development for metastatic colorectal cancer and other EpCAM-expressing solid tumors. Designed to deliver a cytotoxic payload preferentially to tumor tissue via conditional antibody activation.
  • CX-801 A masked (conditionally activated) interferon alpha-2b Probody cytokine designed to concentrate interferon activity within the tumor microenvironment while limiting systemic exposure and associated toxicity.
  • CX-908 A Probody-format T-cell engager bispecific targeting P-Cadherin on tumor cells and CD3 on T cells, designed to engage T-cell cytotoxicity preferentially in tumor tissue and reduce systemic T-cell activation.
  • Probody Therapeutic Platform CytomX's proprietary antibody engineering platform that generates conditionally activated biologics by incorporating a masking peptide linked via a protease-cleavable substrate, restricting activity to protease-rich environments such as tumors. The platform underpins both CytomX's internal pipeline and partner programs with Regeneron, Bristol-Myers Squibb, Amgen, and Moderna.

Quantifiable outcome

  • 32% confirmed response rate at 10 mg/kg dose in late-line metastatic colorectal cancer patients
  • +3 more outcomes

Companies that use CytomX Therapeutics

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

CytomX Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CytomX Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered secondary, core and minor.

  • ModernasecondaryStrategic or Co-development Partner · 1 January 2023Strategic collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies for cancer and other diseases. CytomX received $35 million upfront including $5 million pre-paid research funding. Potential milestones up to approximately $1.2 billion plus tiered royalties on global net sales. Moderna leads clinical development and commercialization.
  • Regeneron PharmaceuticalscoreStrategic or Co-development Partner · 3 March 2022Strategic collaboration to create conditionally-activated investigational bispecific cancer therapies combining CytomX's Probody platform with Regeneron's Veloci-Bi bispecific antibody platform. Initial agreement (2022) valued at up to $2 billion plus royalties. Expanded June 2026 with $37 million target selection payment for two additional programs, bringing total potential value to $4 billion with option for six more targets. CytomX receives upfront, milestone, and tiered global net sales royalty payments.
  • Astellas PharmaminorStrategic or Co-development Partner · 1 March 2020Collaboration to co-develop Probody T-cell-engaging bispecific therapeutics targeting CD3 receptor and select oncology targets. Originally valued at up to $1.68 billion with $80 million upfront. Astellas terminated the partnership in Q2 2025 after choosing not to advance remaining preclinical programs, despite positive Phase 1 data for CytomX's Probody platform.
  • AmgensecondaryStrategic or Co-development Partner · 1 January 2017Strategic immuno-oncology collaboration focused on research and development of T-cell-engaging bispecific therapeutics. Lead program CX-904 was discontinued in 2025 by mutual decision. Amgen has exclusive worldwide rights to develop up to three additional undisclosed targets, with CytomX eligible for upfront, milestone payments and high single-digit to mid-double digit royalties. CytomX also received rights to a preclinical T-cell engaging bispecific program.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 1 January 2014Research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple targets using CytomX's Probody platform. Expanded in 2017 with $200 million upfront payment. Five oncology targets selected, with two remaining in preclinical development. CytomX eligible for future development, regulatory and sales milestone payments plus tiered royalties on net sales.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

CytomX Therapeutics competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage ADC developer building a pipeline of conditionally activated and immune-stimulatory ADCs in oncology. Highly comparable to CytomX's Probody ADC approach in technology class, clinical-stage profile, and partnership-driven business model.
  • ImmunoGen (acquired by AbbVie): Pioneer in antibody-drug conjugates for oncology, now part of AbbVie. Direct precedent for clinical-stage ADC platform companies achieving strategic exits, validating CytomX's ADC-centric pipeline strategy.
  • Xencor: Clinical-stage biotech engineering monoclonal antibodies and bispecifics with XmAb platform technology. Comparable in platform-based engineering of antibody therapeutics and partnership-driven monetization.
  • MacroGenics: Clinical-stage oncology biotech developing bispecific antibodies and ADCs. Comparable clinical-stage pipeline, oncology focus, and reliance on strategic pharma partnerships.
  • Harpoon Therapeutics (acquired by Merck): Developed T-cell engaging bispecifics (TriTAC platform) for solid tumors, recently acquired by Merck. Comparable T-cell engager strategy and clinical-stage oncology focus, providing a recent exit benchmark for CytomX's bispecific work.

Emerging players

  • ProfoundBio: Privately held, clinical-stage ADC developer focused on next-generation oncology therapeutics. Comparable emerging ADC player leveraging proprietary linker-payload technology with similar therapeutic ambitions.
  • Compass Therapeutics: Clinical-stage bispecific antibody developer in oncology. Comparable small-cap clinical biotech with platform technology and partnership opportunities in bispecific antibody space.

Broad incumbents

  • Regeneron Pharmaceuticals: Major biopharma developing Veloci-Bi bispecifics and antibody therapeutics; also a CytomX collaboration partner. Comparable as a broad incumbent in bispecific antibody development that validates CytomX's target space.
  • Amgen: Pioneer of BiTE T-cell engager platform and active ADC developer; also a CytomX partner. Comparable as a large incumbent whose platform choices (and recent CX-904 discontinuation) directly influence CytomX's competitive context.
  • Bristol Myers Squibb: Global biopharma with established immunotherapy, ADC, and bispecific franchises; longstanding CytomX collaboration partner since 2014. Relevant as both strategic partner and broader benchmark for the oncology platform partnering model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights6 records

Customer concentration

CytomX Therapeutics social profiles

Digital presence

CytomX Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CytomX Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

CytomX Therapeutics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CytomX Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytomX Therapeutics

What does CytomX Therapeutics do?

CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics (Probodies) for cancer treatment. Its pipeline includes lead candidate Varseta-M (CX-2051), an EpCAM-targeting antibody-drug conjugate for metastatic colorectal cancer, plus CX-801 (masked interferon alpha-2b cytokine) and CX-908 (a P-Cadherin x CD3 Probody T-cell engager). The company's core innovation is the Probody platform, which masks antibody activity until cleavage by tumor-associated proteases.

Is CytomX Therapeutics a public or private company?

CytomX Therapeutics is a public company. It is classified as public and is currently operating.

When was CytomX Therapeutics founded?

CytomX Therapeutics was founded in 2010. It employs 101 to 250 people.

Where is CytomX Therapeutics based?

CytomX Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does CytomX Therapeutics make money?

Two revenue lines are on record. Partnership/Collaboration Revenue is the primary driver. The others are public Stock Offering.

Who are CytomX Therapeutics's main competitors?

Direct peers on record are Mersana Therapeutics, ImmunoGen (acquired by AbbVie), Xencor, MacroGenics and Harpoon Therapeutics (acquired by Merck). Emerging players are ProfoundBio and Compass Therapeutics. Broad incumbents are Regeneron Pharmaceuticals, Amgen and Bristol Myers Squibb.

Does CytomX Therapeutics have an API?

No public API is recorded for CytomX Therapeutics.

What industry is CytomX Therapeutics in?

CytomX Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldCytomX Therapeutics (NASDAQ:CTMX) and CareDx (NASDAQ:CDNA) Critical AnalysisCytomX Therapeutics and CareDx are compared on profitability, risk, and analyst ratings. CytomX has a stronger consensus rating and higher upside, while CareDx beats on 7 of 13 factors. Analysts favor CytomX despite its higher volatility.Investing.comCytomX at Jefferies Global Healthcare Conference: EpCAM bet gains tractionCytomX Therapeutics presented Varseta-M, its EpCAM-directed antibody drug conjugate, at the Jefferies Global Healthcare Conference, reporting a 20-30% objective response rate in late-line colorectal cancer. The company cited no pancreatic toxicity and reduced grade 3 diarrhea to 10% with prophylactic loperamide and budesonide. It plans a January update with overall survival data and a first pivotal trial in early 2025.Seeking AlphaCytomX Therapeutics: Competitors Impress, Now Its Cytomx's Time To ShineCytomX Therapeutics' Varseta-M antibody-drug conjugate will have updated monotherapy data in January 2027, with prior data showing a 32% confirmed objective response rate. The company reported Q3'26 revenue of $1.7M and a net loss of $20M, with cash expected to last into H2'28. The first registrational trial is set to start in H1'27.American Banking and Market NewsJPMorgan Chase & Co. Issues Positive Forecast for CytomX Therapeutics (NASDAQ:CTMX) Stock PriceJPMorgan Chase lifted its price target on CytomX Therapeutics from $11.00 to $12.00, keeping an overweight rating. The stock opened at $2.04, and the company reported a loss of $0.09 per share, missing estimates. Analysts have a consensus 'Moderate Buy' rating with a target of $12.10.TradingViewJP Morgan maintains CytomX Therapeutics at Overweight, raises price target to $12 from $11JP Morgan maintained CytomX Therapeutics at Overweight and raised its price target to $12 from $11, a 9.1% increase. The target implies an upside of 463.4% from the Nov 11 close of $2.13.American Banking and Market NewsCytomX Therapeutics (NASDAQ:CTMX) Stock Lifted to Hold by Wall Street ZenWall Street Zen upgraded CytomX Therapeutics from Sell to Hold. The company reported Q3 revenue of $1.69 million, missing the $10.38 million estimate, and a loss of $0.09 per share. Analysts have a consensus price target of $12.00.TradingViewWedbush maintains CytomX Therapeutics at Outperform, raises price target to $12 from $11Wedbush maintained CytomX Therapeutics at Outperform and raised its price target to $12 from $11, a 9.1% increase. The target implies an upside of 460.7% from the Nov 5 close of $2.14.The future of tradingCytomX Presents Varseta-M Development Plan Targeting Registrational Study Start in First Half of 2027CytomX Therapeutics plans a registrational study of Varseta-M in relapsed or refractory metastatic colorectal cancer in the first half of 2027. Confirmed objective response rates reached 20% at 8.6 mg/kg and 32% at 10 mg/kg, with preliminary progression-free survival of 6.8 and 7.1 months, respectively. A Phase 1/2 trial combining Varseta-M with bevacizumab and chemotherapy is planned to begin by year-end 2026, with $348 million in cash as of Q3 2026.BenzingaCytomX Therapeutics Q3 2026 Earnings Call Transcript - CytomX Therapeutics (NASDAQ:CTMX)CytomX Therapeutics reported Q3 2026 cash of $348 million and revenue of $1.7 million, down from $6 million year-over-year. The company plans to advance Varseta M into a registrational study in the first half of 2027, with Phase 1 data showing encouraging progression-free survival. It also expects a January update on overall survival.Business & FinancialCytomx Therapeutics To Present At Upcoming November Investor ConferencesCytomX Therapeutics will present at the Guggenheim Healthcare Innovation Conference in Boston on November 9 and the Jefferies Global Healthcare Conference in London on November 18, 2026. The company's clinical-stage pipeline includes Varseta-M, an ADC for metastatic colorectal cancer, and CX-801, a cytokine for metastatic melanoma.